A Phase 1 interventional study of Enlicitide in Healthy and Renal Impairment, sponsored by Merck Sharp & Dohme LLC. Completed at 5 sites in United States. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Renal Insufficiency by Merck & Co., Inc — 2 open to participants now, 2 under way, none of them phase 3. Renal Insufficiency · Merck & Co., Inc.
Among the 32 studies in Renal Insufficiency by Merck & Co., Inc, this one is the 16th largest by enrollment, is one of 2 that started in 2024, is one of 25 in phase 1, and was the 28th registered.
1,413 studies on the registry are indexed under Renal Insufficiency; 145 are open to participants now.
Browse Renal Insufficiency studies →2 of the 32 studies in Renal Insufficiency by Merck & Co., Inc are open now, in 1 country. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States
Ages 18–80 · Healthy volunteers
Merck Sharp & Dohme LLC
Ages 18–80 · Healthy volunteers
By country, each count listing its studies:
Of the 91 Renal Insufficiency studies recruiting now, 48 (53%) set no upper age limit and 18 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 40 across 1,060 interventional studies indexed under Renal Insufficiency.
Median enrollment 26 across the 32 interventional studies. Of the 29 that completed or were terminated, 17 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
2 of the studies in Renal Insufficiency by Merck & Co., Inc that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07734610Merck Sharp & Dohme LLCA Clinical Trial of Nemtabrutinib in Participants With Severe Kidney Disease (MK-1026-027) | 2027-02-01 |
| NCT07922174Merck Sharp & Dohme LLCA Clinical Trial of MK-6916 in Participants With Moderate and Severe Kidney Disease Compared to Healthy Controls (MK-6916-013) | 2027-08-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 32 studies in Renal Insufficiency by Merck & Co., Inc, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Researchers have designed a new study medicine called enlicitide decanoate as a new way to lower the amount of low-density lipoprotein cholesterol (LDL-C) in a person's blood. Enlicitide decanoate will be called "enlicitide" from this point forward, The purpose of this study is to learn what happens to enlicitide in a person's body over time (a pharmacokinetic (PK) study). Researchers will compare what happens to enlicitide in the body when it is given to people with severe renal impairment (meaning the kidneys do not work properly) and to people who are in good health. The researchers believe that the total amount of enlicitide in a person's body measured during the 24 hours after a dose will be similar in people with severe renal impairment and in healthy people.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The main inclusion criteria include but are not limited to the following:
Exclusion Criteria:
The main exclusion criteria include but are not limited to the following:
Panel A: Participants with Severe Renal Impairment:
- History of any illness, other than hypercholesterolemia and Renal Impairment
Panel B: Healthy Participants:
- History of endocrine, GI, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases, other than hypercholesterolemia
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with severe renal impairment receive enlicitide once daily (QD) for 28 days.
Drug: Enlicitide
Healthy participants receive enlicitide QD for 28 days.
Drug: Enlicitide
Oral tablet
Also known as: Enlicitide decanoate, MK-0616
Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24) of Enlicitide
The AUC0-24 of enlicitide in plasma is reported.
Time frame: Day 28 predose and 1, 3, 8, and 24 hours postdose
Maximum Plasma Concentration (Cmax) of Enlicitide
The Cmax of enlicitide is reported.
Time frame: Day 28 predose and 1, 3, 8, and 24 hours postdose
Time to Maximum Plasma Concentration (Tmax) of Enlicitide in Plasma
The Tmax of plasma enlicitide is reported.
Time frame: Day 28 predose and 1, 3, 8, and 24 hours postdose
Apparent Plasma Clearance at Steady State (CLss/F) of Enlicitide
CLss/F of enlicitide is reported.
Time frame: Day 28 predose and 1, 3, 8, and 24 hours postdose
Apparent Plasma Volume of Distribution During Terminal Phase (Vz/F) of Enlicitide
The plasma Vz/F of enlicitide was to be reported. Vz/F was not reported, because blood for PK was only collected for 24 hours post dose at steady state (Day 28), thus the terminal phase could not be characterized, and Vz/F could not be calculated.
Time frame: Day 28 predose and 1, 3, 8, and 24 hours postdose
Number of Participants Who Experience One or More Adverse Events (AEs)
The number of participants with ≥1 AE is reported. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to approximately 42 days
Number of Participants Who Discontinue Study Intervention Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: Up to approximately 28 days
Adult male and female participants on background statin therapy who were either healthy, or had severe renal impairment, were recruited.
| Milestone | Panel A: Severe Renal Impairment Participants | Panel B: Healthy Participants |
|---|---|---|
| Started | 15 | 12 |
| Completed | 15 | 12 |
| Not completed | 0 | 0 |
The AUC0-24 of enlicitide in plasma is reported.
| hr*nmol/L | Panel A: Severe Renal Impairment Participants | Panel B: Healthy Participants |
|---|---|---|
| Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24) of Enlicitide | 347 (296 to 407) | 236 (206 to 271) |
The Cmax of enlicitide is reported.
| nmol/L | Panel A: Severe Renal Impairment Participants | Panel B: Healthy Participants |
|---|---|---|
| Maximum Plasma Concentration (Cmax) of Enlicitide | 17.1 (14.3 to 20.3) | 13.2 (11.1 to 15.7) |
The Tmax of plasma enlicitide is reported.
| Hour | Panel A: Severe Renal Impairment Participants | Panel B: Healthy Participants |
|---|---|---|
| Time to Maximum Plasma Concentration (Tmax) of Enlicitide in Plasma | 5.48 (1.00 to 24.03) | 1.00 (0.83 to 23.45) |
CLss/F of enlicitide is reported.
| Liters/hour | Panel A: Severe Renal Impairment Participants | Panel B: Healthy Participants |
|---|---|---|
| Apparent Plasma Clearance at Steady State (CLss/F) of Enlicitide | 37.1 ± 25.3 | 54.5 ± 20.5 |
The plasma Vz/F of enlicitide was to be reported. Vz/F was not reported, because blood for PK was only collected for 24 hours post dose at steady state (Day 28), thus the terminal phase could not be characterized, and Vz/F could not be calculated.
No measurements were reported for this outcome.
The number of participants with ≥1 AE is reported. An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
| Participants | Panel A: Severe Renal Impairment Participants | Panel B: Healthy Participants |
|---|---|---|
| Number of Participants Who Experience One or More Adverse Events (AEs) | 5 | 2 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
| Participants | Panel A: Severe Renal Impairment Participants | Panel B: Healthy Participants |
|---|---|---|
| Number of Participants Who Discontinue Study Intervention Due to an AE | 3 | 0 |
Collected over Up to ~42 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Panel A: Severe Renal Impairment Participants | 0/15 (0%) | 3/15 (20%) | 4/15 (26.7%) |
| Panel B: Healthy Participants | 0/12 (0%) | 0/12 (0%) | 2/12 (16.7%) |
| Event | Panel A: Severe Renal Impairment Participants | Panel B: Healthy Participants |
|---|---|---|
| Acute myocardial infarctionCardiac disorders | 1/15 | 0/12 |
| Diastolic dysfunctionCardiac disorders | 1/15 | 0/12 |
| InfluenzaInfections and infestations | 1/15 | 0/12 |
| PneumoniaInfections and infestations | 1/15 | 0/12 |
| HyponatraemiaMetabolism and nutrition disorders | 1/15 | 0/12 |
| Acute kidney injuryRenal and urinary disorders | 1/15 | 0/12 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 1/15 | 0/12 |
| Hypertensive urgencyVascular disorders | 1/15 | 0/12 |
| HypotensionVascular disorders | 1/15 | 0/12 |
| Event | Panel A: Severe Renal Impairment Participants | Panel B: Healthy Participants |
|---|---|---|
| Urinary tract infectionInfections and infestations | 0/15 | 1/12 |
| MyalgiaMusculoskeletal and connective tissue disorders | 0/15 | 1/12 |
| Abdominal painGastrointestinal disorders | 1/15 | 0/12 |
| DiarrhoeaGastrointestinal disorders | 1/15 | 0/12 |
| VomitingGastrointestinal disorders | 1/15 | 0/12 |
| Metabolic acidosisMetabolism and nutrition disorders | 1/15 | 0/12 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 1/15 | 0/12 |
| AnxietyPsychiatric disorders | 1/15 | 0/12 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/15 | 0/12 |
| Age, Continuous(Years) | Panel A: Severe Renal Impairment Participants | Panel B: Healthy Participants | Total |
|---|---|---|---|
| Mean | 70.6 ± 10.9 | 67.0 ± 3.8 | 69.0 ± 8.6 |
| Sex: Female, Male(Participants) | Panel A: Severe Renal Impairment Participants | Panel B: Healthy Participants | Total |
|---|---|---|---|
| Female | 7 | 5 | 12 |
| Male | 8 | 7 | 15 |
| Ethnicity (NIH/OMB)(Participants) | Panel A: Severe Renal Impairment Participants | Panel B: Healthy Participants | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 10 | 14 |
| Not Hispanic or Latino | 11 | 1 | 12 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Panel A: Severe Renal Impairment Participants | Panel B: Healthy Participants | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 4 | 1 | 5 |
| White | 11 | 10 | 21 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · externaldatasharing-msd.com
Ran from Nov 2024 to primary completion in Jun 2025, 7 months.
Results were first posted in Oct 2026, 1 year 3 months after primary completion.
Of 212 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 7 months is below that.
Counting every sponsor, half of 230 studies reached it within 8 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enlicitide